The Second Canadian Symposium on Hepatitis C Virus: A Call to Action
In Canada, hepatitis C virus (HCV) infection results in considerable morbidity, mortality and health-related costs. Within the next three to 10 years, it is expected that tolerable, short-duration (12 to 24 weeks) therapies capable of curing >90% of those who undergo treatment will be approved. G...
Saved in:
Main Authors: | Jason Grebely, Marc Bilodeau, Jordan J Feld, Julie Bruneau, Benedikt Fischer, Jennifer F Raven, Eve Roberts, Norma Choucha, Rob P Myers, Selena M Sagan, Joyce A Wilson, Frank Bialystok, D Lorne Tyrrell, Michael Houghton, Mel Krajden, on behalf of the National CIHR Research Training Program in Hepatitis C |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2013/242405 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan
by: Selena M. Sagan, et al.
Published: (2016-01-01) -
The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C
by: Nicholas van Buuren, et al.
Published: (2016-01-01) -
SYMPOSIUM
Published: (2023-01-01) -
Practical Approach to Issues in Virology
by: Mel Krajden
Published: (1996-01-01) -
Symposium Bulletin
Published: (1992-01-01)